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 i g  h  l  i  g  h  t  s
The  effects  of  raloxifene  on  fatty  acid  oxidation  were  examined  in  ovariectomized  rats.
Ketogenesis  was  reduced  and 14CO2 production  from  fatty  acids  was stimulated.
Mitochondrial  and  peroxisomal  -oxidation  of  fatty  acids  were  inhibited.
The  peroxidase-catalized  reaction  of  raloxifene  with  H2O2 led  to NADH  oxidation.
The  pro-oxidant  effect  of raloxifene  can  perturb  important  liver  metabolic  processes.
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a  b  s  t  r  a  c  t
Estrogen  deﬁciency  accelerates  the  development  of  several  disorders  including  visceral  obesity  and
hepatic  steatosis.  The  predisposing  factors  can  be  exacerbated  by  drugs  that  affect  hepatic  lipid
metabolism.  The  aim  of the  present  work  was to determine  if raloxifene,  a selective  estrogen  receptor  mod-
ulator  (SERM)  used  extensively  by postmenopausal  women,  affects  hepatic  fatty  acid oxidation  pathways.
Fatty  acids  oxidation  was  measured  in  the  livers,  mitochondria  and  peroxisomes  of  ovariectomized  (OVX)
rats.  Mitochondrial  and  peroxisomal  -oxidation  was  inhibited  by raloxifene  at  a concentration  range  of
2.5–25  M.  In perfused  livers,  raloxifene  reduced  the  ketogenesis  from  endogenous  and exogenous  fatty
acids  and  increased  the -hydroxybutyrate/acetoacetate  ratio.  An increase  in 14CO2 production  withoutatty acid oxidation
iver
itochondria
eroxisomes
variectomy
a  parallel  increase  in the oxygen  consumption  indicated  that  raloxifene  caused  a  diversion  of NADH  from
the  mitochondrial  respiratory  chain  to another  oxidative  reaction.  It  was  found  that  raloxifene  has  a
strong  ability  to  react  with  H2O2 in  the  presence  of  peroxidase.  It is likely  that the  generation  of  phenoxyl
radical  derivatives  of raloxifene  in  intact  livers  led  to the  co-oxidation  of  NADH  and  a shift  of  the  cellular
redox  state  to  an  oxidised  condition.  This  change  can perturb  other  important  liver  metabolic  processes
dependent  on cellular  NADH/NAD+ ratio.. Introduction
Raloxifene is a selective estrogen receptor modulator (SERM)
f the benzothiopene class (Snyder et al., 2000) that has been
sed extensively to preserve the beneﬁcial effects of estrogen in
ostmenopausal women (Delmas et al., 1997; Hochner-Celnikier,
999). Because estrogens are important regulators of metabolic
omeostasis and lipid metabolism (Chen et al., 2009; Nemoto et al.,
000; Campbell and Febbraio, 2001; Foryst-Ludwig and Kintscher,
010), their deﬁciencies have been demonstrated to accelerate
he development of visceral obesity (Carr, 2003; Poehlman et al.,
995), insulin resistance, type 2 diabetes, dyslipidaemia (Stevenson
t al., 1993), hepatic steatosis (non-alcoholic fatty liver disease
∗ Corresponding author. Tel.: +55 44 30114712; fax: +55 44 30114896.
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— NAFLD, Hewit et al., 2004; Mu  et al., 2009), hypertension and
cardiovascular diseases (Mendelson and Karas, 1994). The cellular
mechanisms by which estrogen deﬁciency induces deregulation
of liver metabolism, including hepatic steatosis, have not been
completely elucidated (Hewit et al., 2004; Nemoto et al., 2000).
Most of the evidence of the role of estrogens in liver metabolism
has resulted from the measurement of enzyme expression in
ovariectomized (OVX) rats or aromatase-deﬁcient animals in which
estrogens were administered to the animals. Under these condi-
tions, estrogen regulates the activity and the expression of the key
enzymes involved in glucose transport, glycolysis, the citric acid
cycle, the mitochondrial respiratory chain and fatty acid oxidation
(Chen et al., 2009; Nemoto et al., 2000; Campbell and Febbraio,
Open access under the Elsevier OA license.2001; Foryst-Ludwig and Kintscher, 2010).
It has been observed that certain drugs can precipitate or exacer-
bate steatosis and steatohepatitis by accentuating the predisposing
factors, including those factors associated with estrogen deﬁciency
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Farrel, 2002; Mu et al., 2009). The steatotic phenotype of PPAR
peroxisome proliferator-activated receptor)-null mice, for exam-
le, is exacerbated by etomoxir, which abolishes lipid oxidation
y inhibiting long-chain fatty acid transport into the mitochon-
ria (Djouadi et al., 1998; Farrel, 2002; Mu et al., 2009). Tamoxifen
TAM), the most well-known SERM, acts as an inhibitor of fatty acid
-oxidation and oxidative phosphorylation (Berson et al., 1998;
uquet et al., 2000) and it has demonstrated to induce steatosis,
teatohepatitis and cirrhosis in some women during the treatment
f breast cancer (Oien et al., 1999; Pratt et al., 1995).
Raloxifen, on the other hand, is used in the menopausal period,
n which there is an increased prevalence of lipid metabolism dis-
urbances (Hewit et al., 2004; Mu et al., 2009). Nevertheless, few
tudies have been conducted concerning the effects of RLX on lipid
etabolism in female animals or humans, particularly during their
enopausal period. The purpose of the present work was thus to
xamine the effects of RLX on fatty acid metabolism in an experi-
ental model of estrogen deﬁciency in rats.
The evaluation of the metabolism of a medium-chain and a long-
hain fatty acid can help in the understanding of the mechanisms
mplicated in the possible metabolic alterations, since there are
ifferences in the enzymatic systems responsible for the entry of
hese fatty acids into the liver cells (Guo et al., 2006), the trans-
ormation to acyl-CoA (McGarry and Brown, 1997; Eaton, 2002),
he dependence from l-carnitine for the acyl-CoA entry into the
itochondria and in the enzymes that catalize the ﬁrst steps of
itochondrial -oxidation (McGarry and Brown, 1997). Moreover,
oth the medium- and long-chain fatty acids are also oxidized in
he peroxisomes (Grum et al., 1994; Mannaerts et al., 1979; Piot
t al., 1998; Reddy and Mannaerts, 1994).
For these reasons, in this work the oxidation of octanoate
medium-chain fatty acid) and palmitate (long-chain fatty acid)
as assessed in the perfused livers and in isolated mitochondria
nd peroxisomes from ovariectomized (OVX) rats. The capacity of
aloxifene in the induction of the peroxidase-dependent catalytic
xidation of H2O2 was also measured.
. Materials and methods
.1. Materials and chemicals
Raloxifene, ATP, ADP, NADH, phenylmethylsulfonyl ﬂuoride (PMSF), o-
hthalaldehyde (OPT), horseradish peroxidase type IV, 2′ ,7′-dichloroﬂuorescein
iacetate (DCFH), 2′ ,7′-dichloroﬂuorescein (DCF), 2,4-dinitrophenol (DNP), fatty
cid-free bovine serum albumin (BSA), l-carnitine, thiobarbituric acid, 2,5-
iphenyloxazole (PPO), 2,2-p-phenylene-bis-5-phenyloxazole (POPOP), [14-C]-
ctanoate and [14-C]-palmitate were purchased from Sigma–Aldrich Chemical Co.
St.  Louis, USA). All other reagents were of the best available grade.
.2. Animals
For ovariectomy surgery, rats weighing 130–160 g (6 weeks of age) were anaes-
hetised with ketamine plus xylazine (50 and 5 mg/kg i.p., respectively). Female
ats in metestrus were used as controls (Marcondes et al., 2002). The animals were
oused in polycarbonate cages and their environment was controlled for a 12:12 h
ight–dark cycle starting at 06:00 AM,  at 20–23 ◦C. All animals had free access to
 standard rodent diet (Nuvilab® , São Paulo, Brazil) and tap water. The experi-
ents were conducted three weeks after the ovaries were removed. All experiments
ere conducted in adherence to the guidelines of the Ethics Committee for Ani-
al  Experimentation of the University of Maringá (certiﬁed n. 079/2008). The body
eight and food intake of the rats were assessed each morning. Overnight-fasted
nimals were anaesthetised for blood collection by cardiac puncture. The plasma
lucose concentrations were determined using a glucose analyser (Optium®). The
otal  cholesterol and triacylglyceride levels were analysed by standard methods (kits
f  Gold Analisa®).
.3. Liver perfusionThe non-recirculating perfusion technique described by Scholz and Bücher
1965) was  used. For the surgical procedure, the rats were anaesthetised by i.p. injec-
ion  of sodium pentobarbital (50 mg/kg). The perfusion ﬂuid was  a Krebs/Henseleit
icarbonate buffer (pH 7.4) saturated with an oxygen/carbon dioxide mixturegy Letters 217 (2013) 82– 89 83
(95/5%). The ﬂuid was pumped through a temperature-regulated (37 ◦C) membrane
oxygenator prior to entering the liver via a cannula inserted into the portal vein. The
perfusion ﬂow was constant in each individual experiment, and it was adjusted to
be between 28 and 32 ml/min, depending on the liver weight. Raloxifene (25 M),
octanoate (50 M),  palmitate (0.3 mM),  fatty acid-free bovine serum albumin (50
or  150 M), traces of [1-14C]octanoate (6.7 nCi/ml) or [1-14C]palmitate (1.7 nCi/ml)
were dissolved in the perfusion. The oxygen concentration in the venous perfusate
was monitored with a Teﬂon-shielded platinum electrode. Samples of the efﬂuent
perfusion ﬂuid were collected in 2–4 min  intervals and analysed for acetoacetate,
-hydroxybutyrate and 14CO2 content. Acetoacetate and -hydroxybutyrate were
measured by standard enzymatic procedures (Mellanby and Williamson, 1974;
Williamson and Mellanby, 1974). Carbon dioxide production was measured by
trapping 14CO2 in phenylethylamine (Scholz et al., 1978). The radioactivity was
measured by liquid scintillation spectroscopy. The following liquid scintillation solu-
tion was used: toluene/ethanol (2/1) containing 5 g/l 2,5-diphenyloxazole (PPO) and
0.15  g/l 2,2-p-phenylene-bis-5-phenyloxazole (POPOP). The metabolic rates were
calculated from the input–output differences and the total ﬂow rates and were
referenced to the weight of the liver.
2.4. Isolation of mitochondria and peroxisomes
The livers were homogenised in a medium containing 0.2 M mannitol, 0.075 M
sucrose, 1.0 mM Tris (pH 7.4), 0.2 mM EGTA, 0.1 mM phenylmethylsulfonyl ﬂuoride
(PMSF) and 50 mg%  (w/v) fatty acid-free bovine serum albumin (BSA) (Bracht et al.,
2003a).  The homogenate was fractionated by sequential centrifugations at 536 × g
and 7080 × g for 10 min. After two  wash cycles by suspension and centrifugation at
6392 × g, the ﬁnal mitochondrial pellet was suspended in a small volume of medium
to  yield a protein concentration of 70–80 mg/ml.
For peroxisomes isolation (Natarajan et al., 2006), the livers were excised and
homogenised in 8 volumes of a medium containing 230 mM mannitol, 70 mM
sucrose, 3 mM HEPES and 1 mM EDTA (pH 7.4). The homogenate was ﬁrst cen-
trifuged at 600 × g for 10 min, and then, the mitochondria were pelleted by
centrifugation at 15,000 × g for 5 min. The post-mitochondrial supernatant was then
centrifuged at 39,000 × g for 10 min  to isolate the fraction including peroxisomes,
which was  resuspended and homogenised in 250 mM sucrose containing 1 mM
EDTA and 10 mM Tris HCl (pH 7.3). This suspension was centrifuged at 15,000 × g for
10  min  and the supernatant was again centrifuged at 39,000 × g to isolate the peroxi-
somes, which were resuspended at a ﬁnal protein concentration of approximately
6–15 mg/ml. Protein concentrations were determined according to the method of
Lowry et al. (1951) using BSA as a standard.
2.5. Oxygen consumption by mitochondria oxidising fatty acids and NADH
The  incubation medium contained 2.0 mM potassium phosphate monobasic,
10 mM HEPES (pH 7.2), 0.1 mM EGTA, 130 mM potassium chloride, 5 mM mag-
nesium chloride, 0.1 mM 2,4-dinitrophenol (DNP), 2.5 mM l-malate, 50 mg%  fatty
acid-free BSA and mitochondrial preparation (0.6–1.2 mg/ml) (Garland et al., 1969).
The reaction was initiated by the addition of either 20 M palmitoyl-CoA + 2.0 mM l-
carnitine or 20 M octanoyl-CoA + 2.0 mM l-carnitine. Mitochondria that had been
disrupted by freeze-thawing were used as the source of NADH-oxidase. NADH
(1.0 mM)  was added to 20 mM Tris–HCl (pH 7.4) medium to start the reaction
(Bracht et al., 2003b). RLX was added to the incubation medium 5 min before sub-
strate addition at a concentration range of 2.5–25 M.  RLX was initially dissolved
in  dimethylsulphoxide (DMSO), and the ﬁnal concentration of the solvent was 0.5%
(v/v). Control reactions were performed to exclude the interference of DMSO.
2.6.  Peroxisomal and mitochondrial fatty acyl-CoA oxidase activity
The fatty acyl-CoA oxidase activity was measured according to Small et al.
(1985) with modiﬁcations (Taguchi et al., 1996). The assay mixture contained 11 mM
potassium phosphate buffer (pH 7.4), 40 mM aminotriazole, 0.04 mg/ml horseradish
peroxidase, 104 M DCFH-DA and peroxisomes or mitochondria (approximately
0.3  mg/ml). Triton X-100 (0.02%) or l-carnitine (2 mM)  was  included in the reaction
medium for assays with peroxisomes and mitochondria, respectively. The reaction
was initiated by the addition of 30 M octanoyl-CoA or palmitoyl-CoA. Raloxifene
was added at 10 and 25 M concentrations. The increase in ﬂuorescence (excitation,
503  nm;  emission, 529 nm)  was  recorded over a period of 10 min, and the activity of
fatty acid acyl-CoA oxidase was expressed as nmol DCF produced/min mg  of protein.
The rates of H2O2 production were calculated from the linear regression analysis of
the  curves after subtracting the values of the blank curves.
2.7. NADH oxidation induced by reaction of raloxifene and H2O2 catalysed by
peroxidaseThe reaction mixtures contained 0.1 M Tris–HCl/1.0 mM EDTA buffer (pH 7.4),
raloxifene (0.25–2.0 M),  H2O2 (25 M),  NADH (200 M)  and horseradish peroxi-
dase (HRP) type VI-A (0.1 M).  The reactions were initiated by the addition of H2O2,
and the oxidation of NADH was measured spectrophotometrically at 340 nm (Chan
et  al., 1999).
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Table 1
Characterization of control (CON) and ovariectomized (OVX) female rats. The ﬁnal body weight and plasma levels of glucose, triacylglyceride and total cholesterol were
evaluated on the 21st day after the ovariectomy surgery. The values are expressed as the mean ± SE.
Parameter CON OVX
Initial body weight (g) 157.0 ± 3.0 (n = 9) 159.5 ± 2.5 (n = 11)
Final body weight (g) 205.0 ± 3.20 (n = 9) 236.1 ± 4.38*
+15% (n = 11)
Mean daily food intake (g/day) 18.65 ± 0.47 (n = 9) 19.17 ± 0.62 (n = 11)
Uterine wet weight (g) 0.418 ± 0.08 (n = 6) 0.104 ± 0.015* (n = 6)
−75% p<0.001
Triacylglyceride (mg/dl) 39.4 ± 3.14 (n = 14) 35.46 ± 2.49 (n = 12)
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pTotal  cholesterol (mg/dl) 72.2 ± 4.43 (n = 15) 
Glucose (mg/dl) 105.3 ± 3.47 (n = 15) 
* p ≤ 0.05 when compared with control females, as determined by a Student’s t-t
.8.  Treatment of data
The data in Figures and Tables were expressed as mean ± standard error (SE).
he  statistical signiﬁcance of the differences between parameters among the two
xperimental groups (OVX and CON) was evaluated by means of two-way analysis
f  variance and differences in the same experimental groups were tested by one-
ay  analysis of variance (repeated-measures test, in the perfusion experiments).
igniﬁcant differences among means were identiﬁed by Newman–Keuls testing.
tudent’s t-test was used when only two mean values were compared. The ID50 were
omputed by numerical interpolation by means of a cubic spline function. The results
re  given in the text as probability values (p). p ≤ 0.05 was adopted as a criterion
f  signiﬁcance. Statistical analysis was performed by means of the StatisticaTM or
raphPAD Software programs.
. Results
.1. Characterisation of animals
Three weeks after ovariectomy surgery, the female rats pre-
ented uterus atrophy and increased body weight compared with
he female rats in the metestrus phase despite similar food intake
Table 1). No statistical differences in the plasmatic levels of tria-
ylglyceride, total cholesterol or glucose were observed between
he two groups.
.2. Effects of raloxifene on oxygen consumption, 14CO2
roduction and ketogenesis due to endogenous and exogenous
ubstrates in the livers from control and ovariectomized rats
Fig. 1 illustrates the time course of the experiments in which
he oxidation of endogenous fatty acids (panels A and B), exoge-
ous octanoate (panels C and D) and exogenous palmitate (panels
 and F) were measured in both control (CON) and ovariectomized
OVX) rats. Some of the mean steady-state values obtained from
he perfusion experiments are presented in Table 2 to facilitate their
omparison. The total ketone body production (sum of the acetoac-
tate and -hydroxybutyrate production) and the ratio between
-hydroxybutyrate and acetoacetate production are also shown.
For the endogenous substrates (Figs. A and B), the results
btained from both animal groups were very similar. The infusion of
LX progressively reduced oxygen consumption and acetoacetate
nd -hydroxybutyrate production. The total ketone body produc-
ion decreased by 78% and 74%, respectively, in the livers of the
ON and OVX rats (Table 2). No signiﬁcant alteration was  observed
n the -hydroxybutyrate to acetoacetate ratio.
The oxygen consumption was slightly decreased in both the CON
−17%) and OVX (−14%) series. In contrast, the 14CO2 production
as increased by 89% and 84% in the CON and OVX conditions,
espectively. Upon termination of the RLX infusion, its effects
ended to reverse.The introduction of exogenous octanoate at 50 M concentra-
ion and traces of [1-14C] octanoate resulted in a further increase
n oxygen consumption and acetoacetate and -hydroxybutyrate
roduction in both experimental series (CON, panel C and OVX,81.67 ± 3.95 (n = 12)
103.9 ± 3.36 (n = 12)
panel D). The increase in -hydroxybutyrate was more notice-
able than the increase in acetoacetate, resulting in a substantial
increase in the -hydroxybutyrate/acetoacetate ratio. The ketone
body production increased 54% under the CON condition, but the -
hydroxybutyrate/acetoacetate ratio increased 209% (Table 2). The
corresponding values in livers from the OVX rats was  +42% and
+275%, respectively. The subsequent introduction of 25 M RLX
caused signiﬁcant changes in all of the measured parameters except
oxygen consumption. The changes were similar in both experimen-
tal groups. There was a rapid decrease in the -hydroxybutyrate
production and a progressive decrease in the acetoacetate pro-
duction. These changes led to a substantial decrease in the total
ketone body production and the -hydroxybutyrate/acetoacetate
ratio (Table 2). At the end of the RLX infusion (50 min  of perfusion
time), the ketone body production reduced by 41% and 43% in
the CON and OVX animals, respectively, when compared with the
respective rates measured before the RLX infusion (30 min  of per-
fusion time). The -hydroxybutyrate/acetoacetate ratio decreased
to values near those obtained before the octanoate infusion, indi-
cating a strong change in the redox potential of the NADH/NAD+
couple to a more oxidised state. In contrast to the lack of signiﬁcant
change in oxygen consumption, RLX stimulated 14CO2 production
in the livers from both the control (+42%) and ovariectomized rats
(+48%).
The effects of RLX on the oxidation of exogenous palmitate are
illustrated in Fig. 1 (Panels E and F). The experimental protocol was
the same as that illustrated for octanoate except for the fact that
palmitate was  infused at a higher concentration (0.3 mM)  to more
closely simulate a physiological condition. The palmitate infusion
caused a noticeable increase in -hydroxybutyrate production and
a small reduction in acetoacetate production in the livers from both
the CON (Panel E) and OVX rats (Panel F). The total ketone body
production and the -hydroxybutyrate/acetoacetate ratio were
substantially higher than those observed with 50 M octanoate as
a substrate, indicating higher rates of -oxidation and a shift in the
mitochondrial NADH/NAD+ potential to a more reduced condition
(Table 2). The infusion of 25 M RLX caused a progressive reduction
in -hydroxybutyrate production but an increase in acetoacetate
production. These changes led to a 43% (CON) or 26% (OVX) reduc-
tion of the ketone body production and an 85% (CON) and 66% (OVX)
decrease in the -hydroxybutyrate/acetoacetate ratio at the end of
the RLX infusion when compared with the values before the RLX
infusion. These effects were not reversed upon the end of RLX infu-
sion. The oxygen consumption and the 14CO2 production remained
unaltered during the entire period of RLX infusion in the livers from
both the CON and OVX rats.
From the experiments performed in perfused livers it was evi-
dent that there was not signiﬁcant differences between the CON
and OVX rats in any of the measured metabolic ﬂuxes derived from
endogenous or exogenous fatty acids, and in the absence or in the
presence of RLX. The subsequent experiments were performed in
both CON and OVX conditions and again no signiﬁcant differences
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Fig. 1. Time course of the changes caused by 25 M raloxifene on the metabolic ﬂux due to the oxidation of endogenous fatty acids (A, B) or exogenous octanoate (C, D) and
palmitate (E, F) in perfused livers from CON (A, C, E) and OVX (B, D, F) rats. In panels (A) and (B), traces of [1-14C]octanoate (6.7 nCi/ml) and 50 M fatty acid-free BSA were
added  to the perfusion ﬂuid. In panels C and D, 50 M octanoate, [1-14C]octanoate (6.7 nCi/ml) and 50 M fatty acid-free BSA were infused at 10–70 min. In panels E and F
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nd 14CO2 contents. The oxygen consumption was  measured polarographically. E
ertical  bars represent the SE.
ere found. For this reason, only the experiments performed in
VX rats were shown.
.3. Effects of raloxifene on mitochondrial ˇ-fatty acid oxidation
For mitochondrial -fatty acid oxidation measurements the
atty acids were utilised as acyl-CoA derivatives (octanoyl-CoA,
almitoyl-CoA) in the presence of l-carnitine. RLX was  added
o the incubation medium at ﬁnal concentrations of 2.5, 10 and
5 M.  RLX inhibited -oxidation in a dose-dependent manner
hen octanoyl-CoA was the substrate (Fig. 2A). The ID50 was
1.24 ± 2.38 M.  With palmitoyl-CoA as a substrate (Fig. 2B),m albumin were infused as indicated by the horizontal bars. RLX was infused at a
ampled at 2–4 min  intervals and analysed for the -hydroxybutyrate, acetoacetate
perimental point is the mean of ﬁve to six experiments with identical protocols.
inhibition was  observed only at the highest concentration (25 M).
The oxygen uptake due to NADH oxidation (NADH-oxidase) in
mitochondria disrupted by freeze-thawing was not signiﬁcantly
modiﬁed (Fig. 2C).
3.4. Effects of raloxifene on peroxisomal and mitochondrial
ˇ-fatty acid oxidation
In the peroxisomes (panel A of Fig. 3), RLX inhibited the oxida-
tion of palmitoyl-CoA and octanoyl-CoA. Palmitoyl-CoA oxidation
was reduced by 41% and 59%in the presence of 10 and 25 M RLX,
respectively. With octanoyl-CoA as substrate, the inhibition caused
by 10 and 25 M RLX in peroxisomes was 43% and 83%, respectively.
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Fig. 2. Effects of raloxifene on the oxidation of octanoyl-CoA (A) and palmitoyl-CoA
(B)  and on NADH-oxidase (C) in the mitochondria isolated from the livers of OVX
rats. The oxidation of octanoyl-CoA (A) or palmitoyl-CoA (B) was measured polaro-
graphically in a reaction medium containing 0.1 mM DNP. The reaction was initiated
by  the addition of 20 M octanoyl-CoA + 2.0 mM l-carnitine (A) or 20 M palmitoyl-
CoA + 2.0 mM l-carnitine (B). RLX was  added to the incubation medium 5 min  before
addition of the substrate at concentrations of 2.5, 10 and 25 M. NADH oxidase (C)
was assayed polarographically in mitochondria that were disrupted by freeze thaw-
ing.  Each experimental point is the mean of seven to thirteen (panel A), six to twelve
(panel B) or ﬁve (panel C) experiments with different mitochondrial preparations.
Vertical bars represent the standard errors (SE). Asterisks indicate signiﬁcant differ-
ences between the values in the presence of RLX and the respective control condition
(0.5% DMSO) as revealed by variance analysis with post hoc Newman–Keuls testing
(p ≤ 0.05).
The acyl-CoA oxidase activities were lower in the mitochondria
than in the peroxisomes (panels B of Fig. 3). RLX caused a strong
inhibition in the oxidation of both substrates. With 25 M RLX, the
palmitoyl-CoA and octanoyl-CoA oxidation decreased by 84% and
93%, respectively.3.5. Effects of raloxifene on the catalytic oxidation of NADH
RLX possesses two phenolic groups in its structure (Snyder
et al., 2000). Certain compounds containing phenol or polyphenol
E.R. Martins-Maciel et al. / Toxicology Letters 217 (2013) 82– 89 87
A, Peroxisomes
 0 10 25 0 10 25
0
50
100
150
200
250
Palmitoyl-CoA
Octanoyl-CoA
*
*
*
*
B, Mitochondria
0 10 25 0 10 25
0
50
100
150
200
250
* *
*
*
Palmitoyl-CoA
Octanoyl-CoA
Raloxifene concentration ( M)
R
a
te
 o
f 
D
C
F
H
 o
x
id
a
ti
o
n
 (
p
m
o
l 
m
in
-1
m
g
 p
ro
te
in
-1
)
Fig. 3. The effects of raloxifene on the acyl-CoA oxidase activities in the per-
oxisomes and mitochondria isolated from OVX rats. In (A), the reaction medium
contained peroxisomes (0.3 mg/ml), peroxidase (40 ng/ml), 40 mM aminotrizole,
104 M DCFH-DA and 0.02% Triton X-100. In (B), the reaction medium contained
mitochondria (0.3 mg/ml), peroxidase (0.04 mg/ml), 40 mM aminotrizole, 104 M
DCFH-DA and l-carnitine (2 mM).  RLX was added to the incubation medium 5 min
before addition of the substrate. The reaction was initiated by the addition of
octanoyl-CoA or palmitoyl-CoA (30 M). The increase in ﬂuorescence (excitation,
495; emission, 520 nm)  was recorded. The values represent the mean ± SE of four
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Fig. 4. Dependence of the rate of peroxidase-catalysed NADH oxidation on ralox-
ifene concentration. The rate of NADH oxidation was determined at 340 nm in a
reaction medium containing 0.1 M Tris–HCl/1.0 mM EDTA buffer (pH 7.4), 0.1 M
horseradish peroxidase (HRP), 200 M NADH, 25 M H2O2 and different RLX con-
centrations. Values represent the mean ± SE of three or four separate experiments.o  eight experiments. Asterisks indicate signiﬁcant differences between the values
n  the presence of RLX and the respective control condition as revealed by variance
nalysis with post hoc Newman–Keuls testing (p ≤ 0.05).
roups have been demonstrated to act as electron donors in
he peroxidase-catalysed oxidation of H2O2 (Chan et al., 1999;
onstantin and Bracht, 2008; Galati et al., 2002). This reaction
ay  produce phenoxyl radical derivatives that co-oxidise NADH,
 reaction that can be easily followed spectroscopically. This
lectron-donating property was, thus, assayed for RLX. The data
resented in Fig. 4 indicate that RLX was able to promote this NADH
xidation in the presence of peroxidase and catalytic amounts of
2O2 at a very low RLX concentration (0.25–2 M).
. Discussion
The results of the present study revealed that RLX affects fatty
cid metabolism in the livers from both OVX and CON rats. The
ffects of RLX as well as the biochemical plasmatic parameters and
he fatty acid oxidation in the livers from OVX rats were not sig-
iﬁcantly different from those of female rats in metestrus (CON
ats).Despite this previous conclusion, this study revealed that RLX
ffects fatty acid liver metabolism via complex mechanisms that
iffer from those induced by the most well-known SERM, tamox-
fen (TAM). TAM accumulates in the mitochondria, and it has beenAsterisks indicate signiﬁcant differences between the values in the presence of
RLX  and the control condition as revealed by variance analysis with post hoc
Newman–Keuls testing (p ≤ 0.05).
suggested that it causes steatosis by acting as an inhibitor of both
fatty acid -oxidation and oxidative phosphorylation (Berson et al.,
1998; Tuquet et al., 2000).
Although in perfused livers from both CON and OVX rats RLX
reduced the ketone body production regardless of the nature of the
fatty acid, e.g., endogenous fatty acids, exogenous medium-chain
(octanoate) or long-chain fatty acids (palmitate), there was  not a
parallel reduction in the oxygen consumption or in the 14CO2 pro-
duction from the oxidation of [1-14C]octanoate or [1-14C]palmitate.
In contrast, there was a stimulation in the production of 14CO2 from
[1-14C]octanoate with either endogenous or exogenous octanoate.
These ﬁndings clearly indicated that citric acid cycle was activated
in the presence of RLX, but without a corresponding increase in the
rate of mitochondrial respiratory chain.
The lack of effect of RLX on mitochondrial NADH oxidation
(Panel C of Fig. 2) indicated that RLX does not exert a direct
inﬂuence on the components of the respiratory chain from Com-
plex I to IV. Furthermore, in intact mitochondria, RLX strongly
inhibited the oxidation of octanoyl-CoA and weakly affected the
oxidation of palmitoyl-CoA (Fig. 2A and B). All these ﬁndings sup-
port the view that RLX does not act on a common step of the
-oxidation of medium-chain and long-chain fatty acids, includ-
ing the citric acid cycle and the mitochondrial respiratory chain.
RLX may  act distinctly on the enzymes responsible for the entry
of medium-chain fatty acids and long-chain fatty acids into the
mitochondria or, alternatively, on the enzymes that catalyse the
ﬁrst step of the -oxidation pathway, the acyl-CoA dehydroge-
nases.
Carnitine acyltransferases (CPT I and CPT II) preferentially trans-
fer long-chain fatty acyl-CoA from the cytosol to the mitochondrial
matrix (McGarry and Brown, 1997), and although a carnitine
octanoyl-CoA transferase (COT) is also present in the liver, it is
located only in peroxisomes (Bieber et al., 1981). It is likely that
the entry of octanoyl-CoA into the isolated mitochondria was also
mediated by CAT (McGarry and Brown, 1997; Eaton, 2002). Rat
liver mitochondria contain four acyl-CoA dehydrogenases that act
on short-, medium-, long- or very long-chain fatty acids (McGarry
and Brown, 1997). An inhibitory action on the medium-chain acyl-
CoA dehydrogenase (MCAD) thus appears to be the most plausible
explanation for the higher inhibition of octanoyl-CoA oxidation in
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omparison with palmitoyl-CoA oxidation in isolated mitochon-
ria.
Peroxisomal -oxidation of both octanoyl-CoA and palmitoyl-
oA was equally reduced by RLX (Fig. 3). Peroxisomal -oxidation
iffers from mitochondrial -oxidation in the ﬁrst step of fatty
cid oxidation (Van Veldhoven and Mannaerts, 1999). The perox-
somal desaturation is catalysed by FAD-containing oxidases that
onate electrons directly to molecular oxygen, thereby producing
ydrogen peroxide. Palmitoyl-CoA oxidase oxidises the CoA ester
f medium-, long- and very long-chain fatty acids (Van Veldhoven
nd Mannaerts, 1987, 1999). Inhibition of the activity of palmitoyl-
oA oxidase could thus be an explanation for the effects of RLX on
solated peroxisomes.
According to Mannaerts et al. (1979),  the contribution of per-
xisomes to palmitate oxidation is only 5% of the overall fatty
cid oxidation in isolated hepatocytes. Thus, the metabolic ﬂuxes
ue to fatty acid oxidation in the perfused livers appear to result
redominantly from mitochondrial metabolism. Nevertheless, a
rimary action on mitochondrial enzymes, as discussed above, can-
ot explain some changes caused by RLX in the perfused livers,
articularly the stimulation of 14CO2 production and the decrease
n the -hydroxybutyrate/acetoacetate ratio.
The stimulation of 14CO2 production indicated that the activity
f the citric acid cycle was increased in the perfused livers from
oth the CON and OVX rats. Under normal conditions, the rate of
he citric acid cycle is strictly dependent on NADH re-oxidation via
he mitochondrial respiratory chain. However, a parallel increase
n the oxygen consumption by the livers was not observed. Thus,
 diversion of the NADH generated in the citric acid cycle from
he respiratory chain to another oxidative reaction was  raised as a
ossible explanation for such a phenomenon.
This pro-oxidant action of RLX is consistent with the observed
ecrease in the -hydroxybutyrate/acetoacetate ratio in the per-
used livers, indicating a shift in the mitochondrial redox state to a
ore oxidised condition (Sies et al., 1982; Veech et al., 1970). This
ction also explains the inhibition of ketone body production asso-
iated with the stimulation of citric acid cycle in the perfused livers.
ith a decrease in NADH/NAD+ ratios, the near-equilibrium of the
-hydroxyacyl-CoA dehydrogenase is shifted towards acetoacetyl-
oA, which inhibits acetyl-CoA acetyltransferase (Stermann et al.,
978). The near-equilibrium catalysed by l-malate dehydrogenase
n also shifted in the direction of oxaloacetate, the acceptor of
cetyl CoA in the reaction of citrate synthase (Stermann et al., 1978;
ücher and Sies, 1980).
In support of the pro-oxidant property of RLX, it was demon-
trated that it has a strong ability to oxidise NADH in the presence
f horseradish peroxidase (HRP) and hydrogen peroxide in an
n vitro incubation system (Fig. 4). This enzymatic action has
een demonstrated to occur with many phenolic and polyphe-
olic compounds, including the ﬂavonoids naringenin, hesperetin
nd apigenin and the ﬂavonols quercetin and ﬁsetin (Chan et al.,
999; Constantin and Bracht, 2008). It is believed that peroxidase
atalyses a one-electron oxidation of phenol to phenoxyl radicals
PhO•) (Chan et al., 1999; Galati et al., 2002). These phenoxyl rad-
cals may  be sufﬁciently reactive to co-oxidise NADH to NAD•,
hich in turn can reduce O2 to O2•. The ﬂavonoid derivatives con-
aining a catechol ring, such as quercetin and ﬁsetin, can oxidise
ADH without oxygen uptake, suggesting that NADH undergoes a
wo-electron oxidation by the o-quinone product (Constantin and
racht, 2008).
This bioactivation of RLX in the intact liver requests the pres-
nce of a source of H2O2, NADH, and an enzyme acting similarly
o horseradish peroxidase in the in vitro systems. The H2O2 that is
equired for the pro-oxidant effect of RLX in intact livers can be pro-
ided by both mitochondrial and peroxisomal fatty acid oxidation
s it was clearly demonstrated (Fig. 3). The peroxidase activity, ongy Letters 217 (2013) 82– 89
the other hand, was  possibly mediated by the functional catalase-
peroxidases, which, in the presence of a suitable electron donor
and low levels of H2O2, have been shown to act as peroxidases
(Chelikani et al., 2004).
It was  also reported that raloxifene as well as estradiol and
other SERMs are metabolized to catechols derivatives and further
to electrophilic o-quinones in rat liver microssomes (Yu et al., 2004;
Michalsen et al., 2012). It is likely that this metabolization also con-
tributed to bioactivation of raloxifene in the perfused liver from
both the CON and OVX rats.
Apparently, the bioactive derivatives of raloxifene seem to be
promptly neutralised by reacting with the NADH produced by cell
metabolism. This reaction, however, caused a disturbance in the
redox potential of the NADH/NAD+ couple. In addition to changes in
the fatty acid oxidation, other important metabolic processes that
are modulated by the NADH/NAD+ redox potential may be altered
by RLX, including glycolysis and gluconeogenesis (Kobayashi and
Neely, 1979; Kraus-Friedmann and Feng, 1996). It should be also
mentioned that the o-quinones can covalently modifying DNA and
cellular proteins, a property that has been implicated in the car-
cinogenic action of some SERMs (Bolton et al., 2004). It appears
likely that the effects of RLX reported here in the perfused liv-
ers may occur during the administration of therapeutic doses of
RLX. Raloxifene was active in the perfused livers at a concentra-
tion of 25 M and in isolated organelles at concentrations between
2.5 and 25 M.  Raloxifene has been shown to undergo exten-
sive ﬁrst-pass metabolism in the liver to glucuronide conjugates,
resulting in an absolute bioavailability of nearly 1–2% (Hochner-
Celnikier, 1999). A portal concentration of 25 M would lead, in
principle, to a systemic concentration of 0.25–0.5 M.  The maximal
plasma concentration of RLX in healthy post-menopausal women
has been reported to reach 0.18–2.87 M following single or mul-
tiple oral dose administrations, respectively (Hochner-Celnikier,
1999).
The deprivation of endogenous estrogens is a negative factor
in the induction of NAFLD, obesity and cadiovascular disorders,
particularly after a prolonged period of menopause (Stevenson
et al., 1993; Mendelson and Karas, 1994; Carr, 2003; Hewit et al.,
2004; Mu  et al., 2009). Thus, it is plausible to conclude that a long-
term utilisation of raloxifene in the postmenopausal condition can
potentially exacerbate liver metabolic dysfunctions due to its pro-
oxidant action, a possibility that deserves further experimental
investigation.
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